Search
Bosentan
go.drugbank.com/drugs/DB00559ApprovedInvestigationalBosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. … Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
MK-8245
go.drugbank.com/drugs/DB13024InvestigationalMK-8245 has been used in trials studying the treatment of Type 2 Diabetes Mellitus.
Cefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. … [FDA Label] This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial
Oxytetracycline
go.drugbank.com/drugs/DB00595ApprovedInvestigationalVet approvedA tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.
Azelaic acid
go.drugbank.com/drugs/DB00548ApprovedInvestigationalIt works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear. … It is also produced by _Malassezia furfur_, also known as _Pityrosporum ovale_, which is a species of fungus that is normally found on human skin.
Beeswax
go.drugbank.com/drugs/DB11600ApprovedThe wax obtained from the honeycomb of the bee. It consists primarily of myricyl palmitate, cerotic acid esters and some high-carbon paraffins. Beeswax is used as a stiffening agent in ointments and creams, and enables water to be incorp...
Bexarotene
go.drugbank.com/drugs/DB00307ApprovedInvestigationalBexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Angiotensin II
go.drugbank.com/drugs/DB11842ApprovedInvestigationalAs distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment
Vutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[A249010] More than 130 TTR mutations have been identified so far,[A249015] but the most common one is the replacement of valine with methionine at position 30 (Val30Met). … [A249010] Vutrisiran was approved by the FDA in June 2022.
DL-Methylephedrine
go.drugbank.com/drugs/DB11278ApprovedMethylephedrine is not legally available in the United States, but has been identified in cases of drug abuse [L2836].